fibromyalgia

Abstract Despite growing evidence that the cerebellum contributes to sensory, motor, cognitive, and affective domains, its role in chronic pain remains poorly understood. Fibromyalgia (FM), a rheumatological condition in which chronic pain is a hallmark feature, offers a paradigmatic model. Although neuroimaging studies have reported increased cerebellar activity in response to nociceptive stimuli, its contribution to pain chronification has been largely overlooked. This perspective paper proposes that the cerebellum may play a central role in FM by generating persistent prediction errors. Dysregulation of this mechanism may result in a mismatch…

Read More

new case-control study published in the Annals of Medicine has shed light on the overlooked burden of fibromyalgia among asthma patients.   The research, conducted by Suat Konuk and colleagues from the Department of Chest Diseases, Bolu Abant Izzet Baysal University, Turkey, shows that fibromyalgia is considerably more common in individuals with asthma and may contribute to poorer asthma control. Asthma and fibromyalgia are both chronic conditions that affect quality of life, and emerging evidence suggests that they share inflammatory and neurophysiological mechanisms. However, little is known about how frequently…

Read More

Medical cannabis products help relieve pain and anxiety caused by fibromyalgia, and improve sleep and quality of life, according to a new study of patients enrolled in the UK’s Medical Cannabis Registry. Fibromyalgia is a poorly understood and difficult-to-treat condition that causes widespread body pain, fatigue, insomnia, mood disorders and brain fog. The UK study of nearly 500 fibromyalgia patients found the greatest improvement in symptoms when participants took higher doses of cannabidiol (CBD) daily over an 18-month period. Higher CBD doses were associated with better outcomes compared to lower…

Read More

  Depression Relief, Not Pain Control, Drives Improvement in Fibromyalgia Patients With Emotional Distress: Study Finds Written By : Medha Baranwal Depression Relief, Not Pain Control, Drives Improvement in Fibromyalgia Patients With Emotional Distress: Study Finds facebook icontwitter iconlinkedin icontubmlr iconpinterest icon whatsapp icon Taiwan: A new prospective study published in Seminars in Arthritis and Rheumatism has found that in patients with fibromyalgia (FM) and marked psychological distress, improvement in depression—rather than pain relief alone—was the key driver of overall disease improvement. The research, led by Kuo-Wei Lee from the…

Read More

study has shown use of therapy dogs can help manage the physical and mental health of people suffering fibromyalgia – a chronic, centralised pain sensitivity disorder with no cure. The Purina Institute and the Mayo Clinic have teamed up for a study – Better Together – which shows animal-assisted activity can be effective for patients. A positive emotional-physiological state was achieved after a single session with a therapy dog. Prevalence Between 3% and 6% of the world’s population is estimated to suffer from fibromyalgia, which is characterised by widespread musculoskeletal…

Read More

Tonmya is supplied as a sublingual tablet containing cyclobenzaprine hydrochloride that is taken once daily at bedtime. Its  was supported by multiple clinical trials demonstrating a reduction in pain among patients treated with Tonmya compared with placebo. Recently published data also showed Tonmya led to improvements in other fibromyalgia symptoms including sleep disturbance and fatigue.   “The availability of Tonmya is a momentous day for Tonix, providing the estimated 10 million people living with fibromyalgia a novel treatment that has been shown to address the debilitating, core symptom of this…

Read More

Fibromyalgia is a long-term chronic condition that causes widespread pain in the muscles and soft tissues throughout the body. The illness can affect people of all ages and has a major impact on quality of life, often making even simple, everyday activities difficult. With an estimated 2–8% of the global population affected, the search for treatments that are both effective and affordable could be a game changer for how symptoms are managed for millions of people who live with the condition. In a recent study published in JAMA Network Open, researchers compared amitriptyline, an…

Read More

Key Takeaways The FORWARD trial is a phase 3, double-blind, placebo-controlled study for fibromyalgia, focusing on time to loss of therapeutic response. AXS-14 is a selective norepinephrine reuptake inhibitor, showing efficacy in improving fibromyalgia symptoms like pain, function, and fatigue. SHOW MORE Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs. Advertisement PixelStream/AdobeStock Axsome Therapeutics today announced the first patient has been dosed in the FORWARD phase 3 trial of esreboxetine (AXS-14) for the management of fibromyalgia. The FORWARD (Fibromyalgia Response…

Read More

  In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel sublingual therapy Tonmya has received approval from the U.S. Food and Drug Administration (FDA) – marking the first new drug for Fibromyalgia in more than 15 years. The medication is now commercially available by prescription in U.S. pharmacies, offering new hope to the roughly 10 million American adults affected by this debilitating condition.   A first-in-class, non-opioid approach Tonmya represents a new therapeutic class: a non-opioid, once-daily sublingual tablet designed for…

Read More

Tonix Pharma is preparing to launch the first new therapy for fibromyalgia in the US in 16 years, after claiming FDA approval for Tonmya, an oral drug used to treat the pain associated with the condition. Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to treat adults with fibromyalgia, a common condition causing chronic pain, fatigue, poor sleep, and cognitive dysfunction that is estimated to affect more than 10 million people in the US. It mostly affects women. Tonix is planning to launch…

Read More